Hiring in life sciences? Share your open positions with our professional community. Read more Close

Your cookie settings

This site uses cookies. Some cookies are essential to make the site work and others help us to improve our services. Read more about cookies in our Privacy policy.

Choose your cookie preferences:

Advertisement

Beyond amplification: precision approaches to targeting HER2.

Created on 09 Jul 2026

Authors

Maxwell R Lloyd, Mark D Pegram, Seth A Wander

Published in

Clinical cancer research : an official journal of the American Association for Cancer Research. Jul 09, 2026. Epub Jul 09, 2026.

Abstract

HER2-directed tyrosine kinase inhibitor combinations with trastuzumab represent an emerging strategy for hormone receptor-negative or -positive metastatic breast cancer with activating HER2 mutations. Correlative genomics reveal on-target and downstream molecular evolution during treatment, identifying response patterns and potential acquired resistance mechanisms. Refining precision therapies for HER2-mutant breast cancer remains a priority.

PMID:
42423636
Bibliographic data and abstract were imported from PubMed on 09 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Sign in to post a review. Add review
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Do you recommend this? Please sign in. Yes No

Recommended

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement